[QGEN] Qiagen Thesis 2026: QuantiFERON Latent TB Drives Sample to Insight Molecular Diagnostics Recurring Consumables Growth

Key Takeaways

• QGEN FY2025 revenue ~$2.00-2.20B (+3-8% YoY, ~+5-10% CER) with adj. EPS ~$2.30-2.65 reflecting continued ~$1.30-1.50B aggregate Molecular Diagnostics + ~$0.70-0.85B aggregate Life Sciences revenue mix under continued President + CEO Thierry Bernard since March 2020 (~6-year tenure as Qiagen CEO; selected post-March 2020 succession from Peer Schatz departure + selected post-March 2020 succession from Qiagen Molecular Diagnostics business unit head background + selected primary architect of post-2020-2025 ~"5 pillars of growth" strategy (QuantiFERON + QIAstat-Dx + QIAcuity digital PCR + Sample Technologies + QIAGEN Digital Insights) + post-2020 ~$10B+ aggregate failed Thermo Fisher acquisition rejection + selected various aggregate buyback-driven capital return).
• QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables Pipeline (~$1.30-1.50B Revenue): ~$1.30-1.50B aggregate Molecular Diagnostics segment revenue (~63-68% revenue mix); selected primary QuantiFERON-TB Gold Plus (selected primary ~#1 aggregate global interferon-gamma release assay (IGRA) latent tuberculosis test + selected various aggregate ~$0.40-0.50B aggregate QuantiFERON revenue + selected various aggregate ~+10-20% aggregate QuantiFERON revenue growth + selected various aggregate ~recurring consumables + selected various aggregate CDC + WHO latent TB screening guideline tailwind + selected various aggregate replacement of tuberculin skin test (TST)) + selected various aggregate QIAstat-Dx syndromic multiplex PCR (selected primary respiratory + gastrointestinal + meningitis + selected various aggregate ~$0.10-0.20B aggregate QIAstat-Dx revenue + selected various aggregate ~+15-30% aggregate QIAstat-Dx revenue growth) + selected various aggregate NeuMoDx (high-throughput molecular testing) + selected various aggregate QIAcuity digital PCR (selected various aggregate ~$0.10-0.15B aggregate QIAcuity revenue + selected various aggregate ~+15-30% aggregate QIAcuity revenue growth) + selected various aggregate companion diagnostics (selected primary ~25+ aggregate pharma companion diagnostic partnerships + selected various aggregate therascreen + selected various aggregate liquid biopsy) + selected various aggregate ~85-90% aggregate Molecular Diagnostics recurring consumables + reagents revenue mix.
• Sample Technologies + QIAGEN Digital Insights + Life Sciences Pipeline (~$0.70-0.85B Revenue + Strategic Catalyst): ~$0.70-0.85B aggregate Life Sciences segment revenue (~32-37% revenue mix); selected primary Sample Technologies (selected primary ~#1-2 aggregate global sample preparation / nucleic acid extraction market position + selected various aggregate QIAcube + EZ2 + QIAsymphony + selected various aggregate ~$0.30-0.40B aggregate Sample Technologies revenue + selected various aggregate ~recurring consumables + reagents) + selected various aggregate QIAGEN Digital Insights (selected primary bioinformatics + clinical interpretation software + selected various aggregate ~$0.10-0.15B aggregate QIAGEN Digital Insights revenue + selected various aggregate ~+5-15% aggregate Digital Insights revenue growth + selected various aggregate ~AI/ML genomic interpretation) + selected various aggregate PCR + assay technologies + selected various aggregate genomics + NGS sample prep + selected various aggregate ~$0.20-0.30B aggregate PCR + assay + genomics revenue + selected various aggregate pharma + academic + applied testing (forensics + food safety + veterinary) end-markets + selected various aggregate post-2024-2025 instrument placement + consumables pull-through + bioinformatics + digital insights monetization.
• Capital position + balance sheet: ~$0.00-0.30 aggregate annual dividend (selected primary buyback-focused capital return; selected post-2024 modest dividend initiation considerations); ~$200-700M aggregate FY2025 buybacks; aggregate capital return ~$200-700M FY2025; aggregate cash + investments ~$0.6-1.0B; ~$1.0-1.5B aggregate gross debt + ~$0.0-0.5B aggregate net debt; net leverage ~~0-1.5x Net Debt/EBITDA; investment-grade BBB+/Baa1 credit rating; ~215-225M aggregate diluted shares.
• FY2026 thesis catalysts: QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline (~$1.30-1.50B + QuantiFERON ~#1 global IGRA latent TB test + ~+10-20% QuantiFERON revenue growth + CDC + WHO latent TB screening guideline tailwind + QIAstat-Dx + QIAcuity + NeuMoDx + companion diagnostics + 85-90% recurring consumables mix) + Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline ($0.70-0.85B + Sample Technologies ~#1-2 global sample prep market position + QIAcube + EZ2 + QIAsymphony + QIAGEN Digital Insights bioinformatics + AI/ML genomic interpretation + pharma + academic + applied testing end-markets) + ~$200-700M aggregate FY2025 capital return + Thierry Bernard "5 pillars of growth" + recurring consumables execution.

Company Background

QIAGEN N.V. (NYSE: QGEN; FSE: QIA) is a Netherlands-incorporated / Germany-headquartered molecular diagnostics + sample-to-insight life science company, founded 1984 in Düsseldorf Germany (~41-year heritage; selected primary post-1984 founding focus on nucleic acid sample preparation + selected post-1996 NASDAQ IPO + selected post-2018 FSE listing). Selected post-1996 NASDAQ listing / post-2018 FSE listing (dual-listed NYSE + Frankfurt); selected post-1996-2025 selected various aggregate ~$5B+ aggregate cumulative M&A platform (selected various aggregate Digene/HPV 2007 + Cellestis/QuantiFERON 2011 + Ingenuity 2013 + Exiqon 2016 + STAT-Dx/QIAstat-Dx 2018 + NeuMoDx 2020 + selected various aggregate); selected post-March 2020 Thierry Bernard CEO appointment (selected post-March 2020 succession from Peer Schatz departure); selected post-2020 ~$10B+ aggregate failed Thermo Fisher acquisition rejection (selected primary Qiagen rejected Thermo Fisher bid); selected post-2020-2025 selected various aggregate "5 pillars of growth" strategy execution + cost optimization; HQ Venlo Netherlands / Hilden Germany; ~5,800-6,200 employees globally.

QGEN operates 2 primary segments: Molecular Diagnostics (~63-68% revenue mix; ~$1.30-1.50B; QuantiFERON + QIAstat-Dx + NeuMoDx + QIAcuity + companion diagnostics + clinical molecular testing) + Life Sciences (~32-37% revenue mix; ~$0.70-0.85B; Sample Technologies + QIAGEN Digital Insights + PCR + assay technologies + genomics + applied testing). Geographic mix: Americas ~45-50% + EMEA ~30-35% + Asia Pacific / Rest of World ~20-25%. Recurring consumables + reagents revenue mix: ~85-90% aggregate.

Capital position: ~$0.00-0.30 aggregate annual dividend (buyback-focused capital return); ~$200-700M aggregate FY2025 buybacks; aggregate capital return ~$200-700M FY2025; aggregate cash + investments ~$0.6-1.0B; net leverage ~~0-1.5x Net Debt/EBITDA; investment-grade BBB+/Baa1 credit rating; ~215-225M aggregate diluted shares.

QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables Pipeline (~$1.30-1.50B Revenue)

The QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline is QGEN's foundation thesis: ~$1.30-1.50B aggregate Molecular Diagnostics segment revenue (~63-68% revenue mix); selected primary QuantiFERON-TB Gold Plus (selected primary ~#1 aggregate global interferon-gamma release assay (IGRA) latent tuberculosis test + selected various aggregate ~$0.40-0.50B aggregate QuantiFERON revenue + selected various aggregate ~+10-20% aggregate QuantiFERON revenue growth + selected various aggregate ~recurring consumables + selected various aggregate CDC + WHO latent TB screening guideline tailwind + selected various aggregate replacement of tuberculin skin test (TST)) + selected various aggregate QIAstat-Dx syndromic multiplex PCR (selected primary respiratory + gastrointestinal + meningitis + selected various aggregate ~$0.10-0.20B aggregate QIAstat-Dx revenue + selected various aggregate ~+15-30% aggregate QIAstat-Dx revenue growth) + selected various aggregate NeuMoDx (high-throughput molecular testing) + selected various aggregate QIAcuity digital PCR (selected various aggregate ~$0.10-0.15B aggregate QIAcuity revenue + selected various aggregate ~+15-30% aggregate QIAcuity revenue growth) + selected various aggregate companion diagnostics (selected primary ~25+ aggregate pharma companion diagnostic partnerships + selected various aggregate therascreen + selected various aggregate liquid biopsy) + selected various aggregate ~85-90% aggregate Molecular Diagnostics recurring consumables + reagents revenue mix.

FY2025 QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables dynamics ($1.30-1.50B aggregate revenue): selected continued post-2024 ~+5-10% aggregate Molecular Diagnostics segment revenue growth at CER (selected primary QuantiFERON ~+10-20% aggregate QuantiFERON revenue growth + selected various aggregate CDC + WHO latent TB screening guideline tailwind + selected various aggregate replacement of tuberculin skin test (TST) + selected various aggregate QIAstat-Dx ~+15-30% aggregate QIAstat-Dx revenue growth + selected various aggregate QIAcuity ~+15-30% aggregate QIAcuity revenue growth + selected various aggregate NeuMoDx + companion diagnostics + selected various aggregate ~85-90% aggregate recurring consumables + reagents revenue mix) + ~$1.30-1.50B aggregate Molecular Diagnostics segment revenue + selected various aggregate ~20-25% aggregate Molecular Diagnostics operating margin. Selected post-2024 ~$1.60-1.85 incremental annual EPS contribution as QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline drives incremental recurring consumables margin.

FY2026 catalyst: continued QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline + ~$1.60-1.85 incremental annual EPS contribution under continued Thierry Bernard leadership (~6-year tenure). Selected aggregate ~$1.38-1.60B aggregate FY2026 Molecular Diagnostics segment revenue + selected various ~+6-12% aggregate growth at CER + selected various aggregate QuantiFERON ~+10-20% aggregate QuantiFERON revenue growth + selected various aggregate ~$0.45-0.60B aggregate FY2026 QuantiFERON revenue + selected various aggregate CDC + WHO latent TB screening guideline tailwind + selected various aggregate replacement of tuberculin skin test (TST) + selected various aggregate QIAstat-Dx + QIAcuity + NeuMoDx + companion diagnostics + selected various aggregate ~85-90% aggregate recurring consumables + reagents revenue mix + selected various aggregate ~20-26% aggregate Molecular Diagnostics operating margin. Risks: Roche Diagnostics (Switzerland; SIX ROG; molecular diagnostics leader) + Abbott Laboratories (ABT, ~$170-200B Mcap; molecular diagnostics) + Hologic (HOLX, ~$15-20B; molecular diagnostics + women's health) + bioMérieux (France; EPA BIM; molecular + microbiology + BioFire syndromic) + Cepheid (Danaher; molecular diagnostics + GeneXpert syndromic) + Oxford Immunotec (PerkinElmer/Revvity-acquired; T-SPOT.TB IGRA latent TB competitor) + Thermo Fisher Scientific (TMO, ~$160-200B; molecular diagnostics + Applied Biosystems) + DiaSorin (Italy; BIT DIA; molecular diagnostics) + selected various aggregate molecular diagnostics + IGRA latent TB + syndromic PCR + digital PCR competitive considerations + clinical lab consolidation considerations + reagent + consumables pricing considerations + selected various aggregate CDC + WHO latent TB screening guideline considerations + selected various aggregate companion diagnostics partnership considerations + selected various aggregate FDA + EU IVDR regulatory considerations.

Sample Technologies + QIAGEN Digital Insights + Life Sciences Pipeline (~$0.70-0.85B Revenue + Strategic Catalyst)

The Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline is QGEN's primary growth thesis: ~$0.70-0.85B aggregate Life Sciences segment revenue (~32-37% revenue mix); selected primary Sample Technologies (selected primary ~#1-2 aggregate global sample preparation / nucleic acid extraction market position + selected various aggregate QIAcube + EZ2 + QIAsymphony + selected various aggregate ~$0.30-0.40B aggregate Sample Technologies revenue + selected various aggregate ~recurring consumables + reagents) + selected various aggregate QIAGEN Digital Insights (selected primary bioinformatics + clinical interpretation software + selected various aggregate ~$0.10-0.15B aggregate QIAGEN Digital Insights revenue + selected various aggregate ~+5-15% aggregate Digital Insights revenue growth + selected various aggregate ~AI/ML genomic interpretation) + selected various aggregate PCR + assay technologies + selected various aggregate genomics + NGS sample prep + selected various aggregate ~$0.20-0.30B aggregate PCR + assay + genomics revenue + selected various aggregate pharma + academic + applied testing (forensics + food safety + veterinary) end-markets + selected various aggregate post-2024-2025 instrument placement + consumables pull-through + bioinformatics + digital insights monetization.

FY2025 Sample Technologies + QIAGEN Digital Insights + Life Sciences dynamics: selected primary ~$0.70-0.85B aggregate Life Sciences segment revenue + selected various aggregate Sample Technologies ~#1-2 aggregate global sample preparation / nucleic acid extraction market position + selected various aggregate QIAcube + EZ2 + QIAsymphony + selected various aggregate ~$0.30-0.40B aggregate Sample Technologies revenue + selected various aggregate QIAGEN Digital Insights bioinformatics + clinical interpretation software + selected various aggregate ~$0.10-0.15B aggregate QIAGEN Digital Insights revenue + selected various aggregate ~AI/ML genomic interpretation + selected various aggregate PCR + assay technologies + genomics + NGS sample prep + selected various aggregate pharma + academic + applied testing (forensics + food safety + veterinary) end-markets + selected various aggregate post-2023-2024 academic + pharma research funding normalization + selected various aggregate ~15-20% aggregate Life Sciences operating margin (below Molecular Diagnostics). Selected post-2024 ~$0.70-0.85 incremental annual EPS contribution as Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline drives incremental margin.

FY2026 catalyst: continued Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline + ~$0.70-0.85 incremental EPS contribution. Selected aggregate ~$0.72-0.90B aggregate FY2026 Life Sciences segment revenue + selected various aggregate ~+2-8% aggregate growth at CER + selected various aggregate Sample Technologies ~#1-2 aggregate global sample preparation market position + selected various aggregate QIAcube + EZ2 + QIAsymphony + selected various aggregate QIAGEN Digital Insights bioinformatics + ~AI/ML genomic interpretation + selected various aggregate ~+5-15% aggregate Digital Insights revenue growth + selected various aggregate PCR + assay + genomics + selected various aggregate pharma + academic + applied testing end-markets + selected various aggregate ~15-22% aggregate Life Sciences operating margin (improvement; instrument placement + consumables pull-through + cost optimization). Risks: Thermo Fisher Scientific (TMO; Applied Biosystems + sample prep) + Roche (sample prep + sequencing) + Illumina (ILMN, ~$15-25B Mcap; NGS sequencing + sample prep) + Danaher / Beckman Coulter / IDT (genomics + sample prep) + Bio-Rad (BIO, ~$8-12B; Droplet Digital PCR + sample prep) + Promega (private; reagents + sample prep) + New England Biolabs (private; reagents) + Agilent Technologies (A, ~$30-40B; genomics + sample prep) + selected various aggregate sample preparation + bioinformatics + genomics competitive considerations + academic + pharma research funding cycle considerations + NIH budget considerations + China research demand cycle considerations + selected various aggregate instrument placement + consumables pull-through considerations + selected various aggregate bioinformatics + digital insights monetization considerations + selected various aggregate applied testing (forensics + food safety + veterinary) cycle considerations.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0.00-0.30 aggregate annual dividend (selected primary buyback-focused capital return; selected post-2024 modest dividend initiation considerations) + ~$200-700M aggregate FY2025 buybacks + aggregate capital return ~$200-700M FY2025 + aggregate cash + investments ~$0.6-1.0B + ~$1.0-1.5B aggregate gross debt + ~$0.0-0.5B aggregate net debt + net leverage ~~0-1.5x Net Debt/EBITDA + investment-grade BBB+/Baa1 credit rating + ~215-225M aggregate diluted shares + weighted average debt maturity ~3-5 years.

FY2026 catalyst: continued ~$200-750M aggregate annual capital return + selected continued buyback-focused capital return policy (selected various aggregate ~$200-700M aggregate annual buybacks + selected post-2024 modest dividend initiation considerations) + selected continued ~~0-1.5x net leverage + selected continued investment-grade BBB+/Baa1 credit rating. Selected buyback-focused capital return policy + selected net cash to modest net debt balance sheet + selected investment-grade BBB+/Baa1 credit rating support continued QuantiFERON Latent TB + Molecular Diagnostics + Sample Technologies + QIAGEN Digital Insights + Life Sciences capacity + tuck-in M&A capacity.

Key Core Metrics

• FY2025 revenue ~$2.00-2.20B (+3-8% YoY, ~+5-10% CER) vs $2.00B FY2024; adj. EPS ~$2.30-2.65
• 2 segments: Molecular Diagnostics ~63-68% ($1.30-1.50B) + Life Sciences ~32-37% ($0.70-0.85B)
• Geographic mix: Americas ~45-50% + EMEA ~30-35% + Asia Pacific / Rest of World ~20-25%
• Recurring consumables + reagents revenue mix: ~85-90% aggregate
• Molecular Diagnostics: QuantiFERON-TB Gold Plus (~#1 global IGRA latent TB test; ~$0.40-0.50B revenue; +10-20% growth) + QIAstat-Dx syndromic PCR ($0.10-0.20B; +15-30% growth) + NeuMoDx + QIAcuity digital PCR ($0.10-0.15B; ~+15-30% growth) + companion diagnostics (~25+ pharma partnerships + therascreen + liquid biopsy)
• Molecular Diagnostics operating margin: ~20-25% aggregate
• Life Sciences: Sample Technologies (~#1-2 global sample prep / nucleic acid extraction; QIAcube + EZ2 + QIAsymphony; ~$0.30-0.40B revenue) + QIAGEN Digital Insights (bioinformatics + clinical interpretation; ~$0.10-0.15B revenue; +5-15% growth; AI/ML genomic interpretation) + PCR + assay + genomics ($0.20-0.30B revenue)
• Life Sciences operating margin: ~15-20% aggregate (below Molecular Diagnostics)
• End-markets: clinical + pharma + academic + applied testing (forensics + food safety + veterinary)
• CDC + WHO latent TB screening guideline tailwind (QuantiFERON replacement of tuberculin skin test)
• post-2020 "5 pillars of growth" strategy: QuantiFERON + QIAstat-Dx + QIAcuity + Sample Technologies + QIAGEN Digital Insights
• post-2020 ~$10B+ aggregate failed Thermo Fisher acquisition rejection
• Aggregate adj. EBITDA: ~$0.60-0.75B FY2025
• Net leverage ~~0-1.5x Net Debt/EBITDA
• ~215-225M aggregate diluted shares; ~$200-700M total capital return FY2025
• Dividend ~$0.00-0.30 annual (buyback-focused capital return; post-2024 modest dividend initiation considerations)
• ~$200-700M aggregate FY2025 buybacks
• Investment-grade BBB+/Baa1 credit rating
• ~5,800-6,200 employees globally
• Thierry Bernard CEO since March 2020 (~6-year tenure; ex-Qiagen Molecular Diagnostics business unit head)
• HQ Venlo Netherlands / Hilden Germany; dual-listed NYSE + Frankfurt; founded 1984 Düsseldorf Germany

Market Evaluation

QGEN FY2026 market evaluation: at ~$40-55 share price + ~215-225M aggregate diluted shares = ~$9-12B market cap; ~$0.00-0.30 aggregate annual dividend + ~$200-700M aggregate annual buyback capacity. Selected primary QGEN peers: Roche Diagnostics (Switzerland; SIX ROG; molecular diagnostics leader) + Abbott Laboratories (ABT, ~$170-200B Mcap; molecular diagnostics) + Hologic (HOLX, ~$15-20B; molecular diagnostics + women's health) + bioMérieux (France; EPA BIM; molecular + microbiology + BioFire syndromic) + Cepheid (Danaher; molecular diagnostics + GeneXpert) + Thermo Fisher Scientific (TMO, ~$160-200B; life science tools + diagnostics) + Danaher (DHR, ~$150-180B; life science tools + diagnostics) + Bio-Rad (BIO, ~$8-12B; Droplet Digital PCR + diagnostics) + Illumina (ILMN, ~$15-25B; NGS sequencing) + Revvity / PerkinElmer (RVTY, ~$10-15B; life sciences + diagnostics + Oxford Immunotec T-SPOT.TB) + Agilent Technologies (A, ~$30-40B; life science instruments) + DiaSorin (Italy; BIT DIA; molecular diagnostics) + selected various aggregate molecular diagnostics + life science tools companies. Selected QGEN ~16-24x P/E (molecular diagnostics + sample-to-insight life science with QuantiFERON ~#1 global IGRA latent TB test + ~85-90% recurring consumables + reagents mix + QIAstat-Dx + QIAcuity + companion diagnostics + Sample Technologies + QIAGEN Digital Insights + "5 pillars of growth") + selected ~4-6x P/Sales + selected ~13-18x EV/EBITDA + selected ~$0.00-0.30 dividend + selected aggregate ~$2.10-2.35B aggregate FY2026 revenue + selected aggregate ~$2.55-2.95 aggregate FY2026 EPS + selected aggregate ~$200-750M aggregate FY2026 capital return + selected aggregate QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables + Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline. FY2026 base case: ~$2.10-2.35B aggregate revenue + ~$2.55-2.95 adj. EPS + ~$200-750M aggregate capital return. Bull case: QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline acceleration (QuantiFERON ~+10-20% revenue growth + CDC + WHO latent TB screening guideline tailwind + replacement of tuberculin skin test + QIAstat-Dx ~+15-30% revenue growth + QIAcuity ~+15-30% revenue growth + companion diagnostics + ~85-90% recurring consumables mix + ~20-26% Molecular Diagnostics operating margin) + Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline acceleration (Sample Technologies ~#1-2 global sample prep market position + QIAGEN Digital Insights AI/ML genomic interpretation + instrument placement + consumables pull-through + academic + pharma research funding normalization + ~15-22% Life Sciences operating margin) drives ~$2.25-2.50B aggregate revenue + ~$2.85-3.30 EPS. Bear case: Roche + Abbott + Hologic + bioMérieux + Cepheid + Thermo Fisher + Danaher + Bio-Rad + Illumina + Revvity (Oxford Immunotec T-SPOT.TB) + DiaSorin competitive intensification + molecular diagnostics + IGRA latent TB + syndromic PCR + digital PCR competitive considerations + clinical lab consolidation considerations + reagent + consumables pricing considerations + CDC + WHO latent TB screening guideline considerations + academic + pharma research funding cycle considerations + NIH budget considerations + China research demand cycle considerations + companion diagnostics partnership considerations + FDA + EU IVDR regulatory considerations + post-March 2020 Thierry Bernard CEO succession planning considerations (~6-year tenure) drives ~$2.00-2.10B revenue + ~$2.20-2.50 EPS. The thesis depends on QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables + Sample Technologies + QIAGEN Digital Insights + Life Sciences + QuantiFERON ~#1 global IGRA latent TB test + ~85-90% recurring consumables + reagents mix + CDC + WHO latent TB screening guideline tailwind + Thierry Bernard "5 pillars of growth" + recurring consumables execution.